Shares of Balaji Amines surged more than 2% during Wednesday’s session following the company’s announcement that it has received regulatory consent to manufacture ISOPROPYLAMINE (MIPA/DIPA). The stock climbed 2.34% to ₹1,711.90 on the NSE, adding ₹39.20 over the previous close of ₹1,672.70. The day’s trading range was between ₹1,656.50 and ₹1,729.90.
In an exchange filing on June 25, Balaji Amines informed that it has received the necessary regulatory consent to begin manufacturing ISOPROPYLAMINE at its facilities. The company said trial runs will commence soon, with full-scale commercial production to follow shortly thereafter.
The development is seen as a positive expansion in Balaji Amines’ product portfolio, strengthening its position in the amine derivatives market. This regulatory approval aligns with the company’s ongoing strategy to widen its specialty chemicals manufacturing capacity.
As of the latest update, Balaji Amines’ market capitalization stands at ₹5,578 crore, with a P/E ratio of 35.39. The stock has traded within a 52-week range of ₹1,127.55 to ₹2,549.75.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
